{"schema_version":"secwatch.filing_event.v1","accession":"0001824293-22-000079","form_type":"8-K","ticker":"GRI","cik":"0001824293","company_name":"GRI Bio, Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.396403+00:00","generated_at":"2026-06-22T09:48:09.608693+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Vallon Pharma Q3 net loss $1.0M; cash $5.2M; strategic review ongoing","bullets":["Net loss of $1.0M for Q3 2022; R&D expenses reversed to $(18,000) vs $0.2M in Q3 2021.","G&A expenses $1.4M, up from $1.0M, driven by $0.6M in strategic evaluation costs.","Cash, cash equivalents and marketable securities of $5.2M as of Sept 30, 2022.","Strategic alternatives review with Ladenburg Thalmann remains ongoing; no transaction guaranteed."],"urls":{"canonical":"https://secwatch.observer/filing/0001824293-22-000079","json":"https://secwatch.observer/filing/0001824293-22-000079.json","markdown":"https://secwatch.observer/filing/0001824293-22-000079.md","text":"https://secwatch.observer/filing/0001824293-22-000079.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1824293/000182429322000079/0001824293-22-000079-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1824293/000182429322000079/ck00018242493-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T09:48:09.608693+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"922f821a7b34318b24a1c126060a85d0bd1e4b63","claim":"GRI Bio, Inc. reported financial results for the quarter ended September 30, 2022.","evidence_excerpt":"On November 3, 2022, Vallon Pharmaceuticals, Inc. (the Company) issued a press release announcing its financial results for the quarter ended September 30, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1824293/000182429322000079/0001824293-22-000079-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}